Advertisement
Screener

Immuneering Corporation (IMRX) Graph

IMRX Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue (m); Cost of revenue (m); Research and development $14.00M; Operating expenses $19.00M.
  • 2026-03-31: Revenue (m); Cost of revenue (m); Research and development $10.65M; Operating expenses $15.34M.
  • 2025-12-31: Revenue (m); Cost of revenue (m); Research and development $9.25M*; Operating expenses $13.75M*.
  • 2025-09-30: Revenue (m); Cost of revenue (m); Research and development $10.87M; Operating expenses $15.38M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentOperating expensesNet income
2026-06-30(m)(m)$14.00M$19.00M-$17.27M
2026-03-31(m)(m)$10.65M$15.34M-$13.46M
2025-12-31(m)(m)$9.25M*$13.75M*-$11.58M*
2025-09-30(m)(m)$10.87M$15.38M-$14.96M
2025-06-30(m)(m)$10.45M$14.76M-$14.43M
2025-03-31(m)(m)$11.47M$15.48M-$15.05M
2024-09-30(m)(m)$11.25M$15.27M-$14.60M
2024-06-30(m)(m)$10.65M$14.91M-$14.08M
2024-03-31(m)(m)$11.20M$15.33M-$14.31M
2023-12-31$0.00*$0.00*(m)(m)(m)
2023-09-30$0.00$0.00$10.05M$13.93M-$12.60M
2023-06-30$0.00$0.00$9.45M$13.50M-$12.19M
2023-03-31$0.00$0.00$10.21M$14.68M-$13.60M
2022-09-30$38.38K$19.34K$9.36M$13.21M-$12.84M
2022-06-30$94.42K$47.93K$7.98M$11.69M-$11.53M
2022-03-31$183.70K$90.85K$9.06M$13.02M-$12.90M
2021-09-30$482.13K$219.09K$6.21M$8.81M-$8.53M
2021-06-30$660.04K$318.60K$6.99M$8.33M-$7.99M
2021-03-31$748.20K$409.16K$5.39M$6.58M-$6.23M
2020-09-30$682.57K$315.00K$4.07M$4.77M-$4.40M
2020-06-30$480.83K$237.06K$3.22M$3.85M-$3.60M
2020-03-31(m)(m)(m)(m)-$3.20M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentOperating expensesNet income
2026-06-30(m)(m)$24.64M$34.34M-$30.73M
2025-06-30(m)(m)$21.93M$30.24M-$29.48M
2024-06-30(m)(m)$21.85M$30.24M-$28.39M
2023-06-30$0.00$0.00$19.66M$28.18M-$25.79M
2022-06-30$278.12K$138.78K$17.03M$24.71M-$24.42M
2021-06-30$1.41M$727.76K$12.38M$14.91M-$14.22M
2020-06-30$963.88K$492.09K$6.04M$7.32M-$6.80M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentOperating expensesNet income
2025-09-30(m)(m)$32.79M$45.62M-$44.44M
2024-09-30(m)(m)$33.11M$45.51M-$42.99M
2023-09-30$0.00$0.00$29.71M$42.11M-$38.39M
2022-09-30$316.50K$158.12K$26.40M$37.92M-$37.27M
2021-09-30$1.89M$946.85K$18.59M$23.71M-$22.75M
2020-09-30$1.65M$807.09K$10.11M$12.09M-$11.20M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31(m)(m)$42.05M$59.38M$0.00-$56.02M
2024-12-31(m)(m)$47.96M$64.07M(m)-$61.04M
2023-12-31$0.00$0.00$41.62M$58.41M(m)-$53.47M
2022-12-31$316.95K$158.12K$36.27M$51.90M(m)-$50.51M
2021-12-31$2.08M$1.15M$26.54M$34.81M-$307.49K-$33.54M
2020-12-31$2.31M$1.28M$15.00M$18.11M(m)-$17.04M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Quantum Cyber N.V. (QUCY)$0.113B
BICYCLE THERAPEUTICS PLC (BCYC)$0.112B-1.56
GENELUX Corp (GNLX)United States$0.110B-3.83
Equillium, Inc. (EQ)United States$0.109B-11.27
OnKure Therapeutics, Inc. (OKUR)United States$0.119B-3.13
Biomea Fusion, Inc. (BMEA)United States$0.107B-3.30
Polaryx Therapeutics, Inc. (PLYX)United States$0.106B
Coya Therapeutics, Inc. (COYA)United States$0.121B-6.35
CUMBERLAND PHARMACEUTICALS INC (CPIX)United States$0.121B-8.95
Aardvark Therapeutics, Inc. (AARD)United States$0.121B-1.80